Myriad Genetics specializes in molecular diagnostic testing, offering genetic screening and analysis to help inform medical decisions in cancer, women’s health, and mental health. Its products are ...
First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over ...
On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...
Q4 2025 earnings call recap: revenue beat, MyRisk/GeneSight growth, 2026 guidance, new test launches & key risks—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results